Genedrive Share Chat (GDR)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Genedrive	LSE:GDR	London	Ordinary Share	GB00B1VKB244	ORD 1.5P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	24.50p	21.00p	28.00p	24.50p	24.50p	24.50p	0	05:30:37

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	3.2	-7.5	-34.9	-	4.60

Genedrive Share Discussion Threads

Showing 26 to 43 of 50 messages

Chat Pages: 2 1

Date	Subject	Author	Discuss
24/8/2018 09:49	Woops!!!!! 656Public companies: duty of directors to call meeting on serious loss of capital (1)Where the net assets of a public company are half or less of its called-up share capital, the directors must call a general meeting of the company to consider whether any, and if so what, steps should be taken to deal with the situation. (2)They must do so not later than 28 days from the earliest day on which that fact is known to a director of the company. (3)The meeting must be convened for a date not later than 56 days from that day. (4)If there is a failure to convene a meeting as required by this section, each of the directors of the company who— (a)knowingly authorises or permits the failure, or (b)after the period during which the meeting should have been convened, knowingly authorises or permits the failure to continue,commits an offence. (5)A person guilty of an offence under this section is liable— (a)on conviction on indictment, to a fine; (b)on summary conviction, to a fine not exceeding the statutory maximum. (6)Nothing in this section authorises the consideration at a meeting convened in pursuance of subsection (1) of any matter that could not have been considered at that meeting apart from this section.	pugugly	Read Full Thread Reply
02/11/2017 07:18	Sounds possibly fatal to the TB India programme ! https://www.investegate.co.uk/genedrive-plc--gdr-/rns/distribution-update-for-india/201711020700053351V/ Only questions are - * How much of a hit will the share price take today ? * What value is left in the company ?	pugugly	Read Full Thread Reply
17/10/2017 14:37	Despite the rise in today’s share price, Genedrive’s results are poor. Revenue missed their £7m forecast and net losses widened to £6.4m, greater than their sales of £5.8m. The problems facing this diagnostic business is two-fold: -One R&D expenses account for 90% of group sales (normally you would expect 20%). Also, it grows larger as sales increase. -Two staff costs represent half of sales. Also, 40% of group sales is reliance on grant funding which is a volatile source of income. But, right now it is helping to mask internal sales weakness within the business. Those who participate in last year placing at 80p is down by 55%. For more Genedrive analysis and other analysis on companies’ results, click http://bit.ly/2hLViFb	walbrock82	Read Full Thread Reply
16/10/2017 11:41	Bought in today for results pretty much MC in bank surely can't go wrong	johns288	Read Full Thread Reply
05/7/2017 11:14	See previous	the ghost who walks	Read Full Thread Reply
11/4/2017 07:34	Previous posts	the ghost who walks	Read Full Thread Reply
30/3/2017 09:21	News. Following closely. See previous	the ghost who walks	Read Full Thread Reply
27/3/2017 11:17	More news today. Monitoring this closely. R@d	the ghost who walks	Read Full Thread Reply
17/3/2017 07:59	Previous posts	the ghost who walks	Read Full Thread Reply
12/3/2017 19:16	See previois	the ghost who walks	Read Full Thread Reply
11/3/2017 19:45	Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.	azzi	Read Full Thread Reply
11/3/2017 19:45	Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.	azzi	Read Full Thread Reply
17/2/2017 21:02	Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!	azzi	Read Full Thread Reply
17/2/2017 21:02	Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!	azzi	Read Full Thread Reply
31/1/2017 19:20	Had it confirmed again that Epistem were working with a world Leading company who strongly advised that they made design changes and improved the sample preparation and cartridge handling protocols. I understand Epistem turned down their recommendations. It appears these are the issues hitting the flagship Tb assay, and preventing its take up in India.	azzi	Read Full Thread Reply
30/1/2017 18:46	See earlier post on gdr	the ghost who walks	Read Full Thread Reply
27/1/2017 17:39	See previous poste	the ghost who walks	Read Full Thread Reply
22/11/2016 09:44	To be clear, I am not a big investor in AIM stocks, Epistem/GDR is my only one, into which I was enticed several years ago. I sold at a loss last year but retain the company on my watch list. Cepheids system is not ldentical to GDR, however they are blessed with a dynamic development team and have many peer reviewed publications out there, yet they are still not breaking into the Indian market Last week I had a day in the Madica conference in Germsny which supports the clinical manufCturing and diagnostic companies. All I could find out about GDR is that they are ploughing ahead with the technology as it stands, though the one delegate who knew the company claimed that they had been working with a big multi national who advised them to make changes to their design and work flow a few years ago. These recommendations were turned down by the old CEO and scientific director apparently. I couldn't find out any more as I had other fish to fry!	azzi	Read Full Thread Reply

Chat Pages: 2 1

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.